Hematologic Oncology

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia.

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

The FDA has approved nilotinib tablets without mealtime restrictions for select patients with chronic myeloid leukemia.

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.